News Articles

Takeda’s Growth and Emerging Markets Business Unit Aims to Deliver Double-Digit Revenue Growth Over Next... OSAKA, Japan & CAMBRIDGE, Mass. -Monday 15 March 2021

Aiming for Revenues of JPY 1 Trillion (approximately US$9 Billion2) by FY2030 Double-Digit Revenue Growth Expected to be Driven by a Balanced and Focused Geographic Presence, Portfolio of 14 Global Brands and Wave 1 Pipeline Assets Commitment to Patient Access to Medicines...

Takeda Submits New Drug Application in Japan for Lanadelumab as a Preventive Treatment for Hereditary Angioedema... -Friday 12 March 2021

— Lanadelumab is an investigational monoclonal antibody for the preventive treatment of hereditary angioedema (HAE) in patients 12 years and older1 — Takeda is committed to bringing important therapies to patients with high unmet medical needs around the world (BUSINESS WIRE)-- Takeda...

Takeda to Acquire Maverick Therapeutics to Advance T-Cell Engager Therapies for Solid Tumors and Expand Novel... -Wednesday 10 March 2021  

Acquisition expands Takeda’s immuno-oncology portfolio with two development candidates and Maverick’s conditionally active bispecific T-cell engagers COBRA™ platform, specifically designed to target solid tumors Maverick’s lead candidate TAK-186 (formerly MVC-101), a conditionally...

Takeda Secures Global Rights from Ovid Therapeutics to Develop and Commercialize Soticlestat for the Treatment of... -Friday 5 March 2021  

− Ovid eligible to receive up to $856M in payments, including a $196M upfront payment, regulatory and commercial milestone payments and tiered double-digit royalties on product sales − Potential first-in-class therapy reduced seizure frequency in children with Dravet syndrome and...

Takeda to Divest Four Diabetes Products in Japan to Teijin Pharma Limited -Monday 1 March 2021

Asset transfer furthers Takeda’s global strategy to focus on five key business areas Takeda will continue to manufacture and supply products to Teijin Pharma, providing uninterrupted access to patients (BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited (TOKYO:4502) (NYSE:TAK)...

Takeda Provides Updates on Phase 1/2 Clinical Trials of Novavax’ and Moderna’s COVID-19 Vaccine Candidates... -Thursday 25 February 2021

(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) announced today that the first subject was dosed in its Phase 1/2 immunogenicity and safety study of Novavax’ COVID-19 vaccine candidate (TAK-019) in Japan. Earlier this month, Takeda completed enrollment in the...

Takeda’s Maribavir Phase 3 Clinical Trial Met Primary Endpoint of Superiority to Conventional Antiviral Therapy in... -Friday 12 February 2021

(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today at the 2021 Transplantation & Cellular Therapy (TCT) Meetings Digital Experience announced new, late-breaking Phase 3 data from the TAK-620-303 (SOLSTICE) trial, for the investigational drug TAK-620...

Takeda Submits New Drug Application to Manufacture and Market Darvadstrocel In Japan for Treatment of Complex Perianal... -Wednesday 10 February 2021

Takeda Applies for Approval for the Company’s First Allogeneic Stem Cell Therapy in Japan If Approved, Darvadstrocel Would Offer a Potential Cell-Mediated Closure Option for Adult Patients in Japan Who Do Not Respond to Conventional or Biologic Therapies for Complex Perianal...

Takeda FY2020 Q3 Results Demonstrate Growth Acceleration and Continued Resilience; Full-Year Management Guidance for... -Saturday 6 February 2021

(BUSINESS WIRE) -- Takeda Pharmaceutical Company Limited (TOKYO:4502/NYSE:TAK) (“Takeda”) today announced financial results for the third quarter of fiscal year 2020 (period ended December 31, 2020). TAKEDA CHIEF FINANCIAL OFFICER COSTA SAROUKOS commented: “Our third-quarter results...

Data at EAHAD 2021 Highlight Value of Takeda’s Leading Hematology Portfolio in Clinical Settings and Commitment to... -Wednesday 3 February 2021

− Seven Year Data Reinforce Long-term Efficacy and Safety Review of ADVATE (Antihemophilic Factor [Recombinant]) − Abstracts Support Use of Real World Evidence to Advance Treatment and Patient Outcomes − Takeda’s Heritage in Bleeding Disorders and Commitment to Investing in...

Takeda Completes Sale of TachoSil® to Corza Health -Monday 1 February 2021

(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it has completed the previously announced sale of TachoSil® Fibrin Sealant Patch (“TachoSil®”) to Corza Health, Inc. (“Corza”) for €350 million. TachoSil® is a surgical...

Takeda Completes Sale of Select OTC and Non-Core Assets to Hypera Pharma -Saturday 30 January 2021

(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the completion of its previously-announced sale of a portfolio of select products sold in Latin America to Hypera S.A. (“Hypera Pharma”) for a total value of $825 million USD. This...

Takeda Presents Positive Results For Mobocertinib in Patients with EGFR Exon20 insertion+ mNSCLC Who Received Prior... -Friday 29 January 2021

Mobocertinib, an oral targeted therapy, demonstrated clinically meaningful responses, with a confirmed objective response rate of 35% as assessed by investigator and 28% as assessed by an independent review committee (IRC) Responses shown with mobocertinib were durable, with a median...

Takeda Achieved Carbon Neutrality in 2020 -Wednesday 27 January 2021

(BUSINESS WIRE) -- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it achieved carbon neutrality in its value chain for its fiscal year 2019. This achievement was delivered by a continued focus on internal energy conservation measures, procurement of...

Takeda Achieves Industry-Leading Positions in 2021 Access to Medicine Index -Wednesday 27 January 2021

(BUSINESS WIRE) -- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) has earned an industry-leading position within the 2021 Access to Medicine (AtM) Index published today. Specifically the company achieved notable, high scores in all three technical areas evaluated...

Takeda Named Global Top Employer for Fourth Consecutive Year -Tuesday 26 January 2021

(BUSINESS WIRE) -- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it is one of only 16 companies to achieve global Top Employer® certification for 2021. In addition to receiving the global certification for the fourth consecutive year, Takeda...

Takeda Provides Pipeline Update and Shares Goal to Increase Revenue 50% by FY2030 at the 39th Annual J.P. Morgan... -Friday 15 January 2021

− Goal to Reach JPY5 Trillion ($47 Billion) Revenue by FY20301, Representing 50% Growth from FY2019 − Wave 1 Pipeline Portfolio Includes 12 New Molecular Entities Targeted for Launch by FY2024 Representing Best-in-Class/First-in-Class Therapies with Significant Market Potential −...

Takeda to Present at The 39th Annual J.P. Morgan Healthcare Conference -Tuesday 12 January 2021

(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK) (“Takeda”) will present virtually at the 39th Annual J.P. Morgan Healthcare Conference at 5:20 p.m. ET on Monday, January 11, 2021 / 7:20 a.m. JT on Tuesday, January 12, 2021. Investors and the general public are...

Takeda Completes Sale of Select Non-Core Assets to Cheplapharm -Wednesday 6 January 2021

(BUSINESS WIRE) -- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the completion of its previously-announced sale of a portfolio of select prescription products to Cheplapharm for a total value of $562 million USD1. The portfolio includes 16 prescription...

U.S. FDA Approves Supplemental New Drug Application for Takeda’s ICLUSIG® (ponatinib) for... -Tuesday 22 December 2020

(BUSINESS WIRE) -- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for ICLUSIG® (ponatinib) for adult patients with chronic-phase (CP) chronic myeloid leukemia...